# A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

Source: https://onco.cc/trials/nct06682780/  
OnCo record `nct06682780` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Docetaxel, Toripalimab, Carboplatin, Niraparib and Lenvatinib in advanced solid tumours, run by LaNova Medicines Limited, now recruiting.

## Summary

A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours is a phase 1/2 interventional study registered as NCT06682780 by LaNova Medicines Limited, with 320 participants planned, started 2025-09-17 and due to reach its primary completion in 2028-12-25. Interventions recorded: LM-2417, Docetaxel, Toripalimab/Tirelizumab, Carboplatin, Niraparib and Lenvatinib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06682780
- Phase: 1/2
- Setting: An Open-label, Dose-escalation, and Dose-expansion Phase I/II Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Efficacy of LM-2417 for Injection Alone or in Combination With Other Antitumor Agents in Patients With Advanced Solid Tumors
- Sponsor: LaNova Medicines Limited
- Enrolled: 320

## Sources

- ClinicalTrials.gov NCT06682780: https://clinicaltrials.gov/study/NCT06682780

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Niraparib](https://onco.cc/drugs/niraparib/), [Toripalimab](https://onco.cc/drugs/toripalimab/)
- companies: [LaNova Medicines](https://onco.cc/companies/lanova-medicines/)

---
JSON: https://onco.cc/api/v1/entities/nct06682780.json